SPACInsider Logo
Valar Doeharis: Arya Sciences Acquisition Corp. Files for $125M SPAC
by Kristi Marvin on 2018-09-12 at 0:26am


Winter is Coming and so is Arya Sciences Acquisition Corp.

Arya Sciences Acquisition Corp. filed for a $125 million SPAC IPO today, with a focus on the healthcare, and more specifically, the life sciences and medical technology sectors.  Additionally, Perceptive Advisors,  one of the most well known life sciences hedge funds, is acting as sponsor.

Arya Sciences is being led by Joseph Edelman, the founder of Perceptive Advisors, as Chairman, and Adam Stone, who is the Chief Investment Officer of Perceptive, as CEO and Director.  If you’re going to be looking in the healthcare space, it’s hard to argue with wanting Perceptive involved.  Perceptive has over $5 billion in assets under management focused exclusively on the healthcare industry so clearly they have some understanding of the sector.

Additionally, Perceptive Advisors will be sponsoring this SPAC via it’s affiliate – Arya Sciences Holdings, and has indicated an interest in purchasing up to $25 million of shares at business combination.  However, an “indication of interest” is sort of like the Coke Zero of backstops.  Tastes like Coke, but without any of the “sugar”.  I.e.,  they say they’re interested, but it doesn’t hold a lot of weight.

A summary of terms has been provided below, but you can review the the profile page with management bios here.

Arya Sciences Summary of Terms:
  • Focus:  Healthcare – Life Sciences/Med Tech
  • Size: $125 million
  • 100.0% held in trust ($10.00 per share)
  • $10.00 unit comprised of one share of Common Stock + 1/2 of a full Warrant 
  • Warrant call for redemption trigger: equals or exceeds $18.00 (cash or cashless exercise)
  • 24 months to complete an acquisition
  • Limitation on Redemption Rights: 15%
  • At-risk Capital: $5.44 million (5,437,500 warrants at $1.00)
  • Indication of Interest: 
    • Arya Science Holdings (an affiliate of Perceptive), the Sponsor, has indicated an interest in purchasing up to $25 million of shares at combination
  • Underwriter fees: 2.75% + 3.25% deferred. 


Jefferies is sole book-running manager and Chardan is lead manager.

Kirkland & Ellis LLP and Skadden, Arps, Slate, Meagher & Flom LLP are Issuer’s Counsel and Underwriter’s Counsel, respectively.


Recent Posts
by Kristi Marvin on 2023-03-25 at 12:14pm

Terms Tracker for the Week Ending March 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. While this week was relatively quiet on the filings front, we did see March’s second SPAC IPO price with Oak Woods Acquisition Corp’s $50 million...

by Marlena Haddad on 2023-03-24 at 5:40pm

Latest Non-Redemption Agreements: ExcelFin Acquisition Corp. ExcelFin Acquisition Corp. (XFIN) Adds Non-Redemption Agreement In connection with the special meeting of stockholders of ExcelFin Acquisition Corp. (NASDAQ:XFIN) to extend its completion deadline from April 25, 2023 to October 25, 2023, the company and its sponsor, ExcelFin SPAC LLC, entered into a non-redemption agreement with an unaffiliated third party....

by Marlena Haddad on 2023-03-24 at 11:33am

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News:  Momentus SPAC backers accused of deliberately engineering a catastrophic deal  Momentus SPAC Backers Accused of Hiding Disastrous Deal’s Flaws A Momentus Inc. (NASDAQ:MNTS) investor sued backers of its blank-check merger with a shell company,...

by Nicholas Alan Clayton on 2023-03-24 at 7:20am

DiamondHead Holdings Corp. (NASDAQ:DHHC) announced in an 8-K this morning that its shareholders approved its combination with Great Southern Homes at a special meeting March 23. Only 109,426 shares were redeemed in the connection with the vote, but DiamondHead has seen about 87% redemptions in total across all previous votes, leaving it with about $43.9...

by Nicholas Alan Clayton on 2023-03-24 at 7:05am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen. This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a...

Privacy Policy|Terms Of Use
Copyright © 2023 SPACInsider, Inc. All Rights Reserved